Details

Autor(en) / Beteiligte

• Schmidt, Keith T.
• Peer, Cody J.
• Huitema, Alwin D.R.
• Williams, Monique D.
• Wroblewski, Susan
• Schellens, Jan H.M.
• Madan, Ravi A.
• Figg, William D.

Titel

Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma

Ist Teil von

• Journal of pharmaceutical and biomedical analysis, 2020-03, Vol.181, p.113073-113073, Article 113073

Ort / Verlag

England: Elsevier B.V

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •NLG207 is a nanoparticle-drug conjugate of camptothecin (topoisomerase I inhibitor).•Analytical methods were developed to measure nanoparticle-bound & free camptothecin.•The pharmacokinetic assay to quantitate plasma concentrations was accurate & precise.•NLG207 samples were stable up to 24 h at 4 °C and following 4 freeze-thaw cycles.•Clinical utility was shown via quantitation of samples from NLG207-treated patients. Camptothecin (CPT), a potent inhibitor of topoisomerase I and HIF-1α, failed to demonstrate utility as an anti-cancer agent in early clinical trial investigations, primarily due to limited clinical activity and significant toxicity attributable to unfavorable physicochemical properties (e.g. low plasma solubility, pH-labile lactone ring). NLG207 (formerly CRLX101), a nanoparticle-drug conjugate (NDC) of CPT designed to optimize plasma pharmacokinetics and facilitate drug delivery to tumors, is included as part of combination treatment in two Phase II clinical trials ongoing at the National Cancer Institute (NCT02769962 and NCT03531827). To better understand the potential for drug-drug interactions and to correlate drug exposure to clinical outcomes and pharmacodynamic biomarkers, a robust analytical method was developed to measure CPT in human plasma. Two sample processing methods were developed to quantify both NDC-bound CPT and free CPT, primarily via alteration of pH conditions. A solid-phase extraction recovered >79 % of CPT prior to quantitative analysis by ultra HPLC-MS/MS. Dynamic calibration ranges of 10 to 10,000 ng/mL and 1 to 1000 ng/mL for total and free CPT, respectively were utilized to capture clinical ranges. NLG207 NDCs demonstrated significant rates of CPT release in human plasma at room temperature after 2 h but were shown to be stable at 4 °C for 24 h and through 4 freeze/thaw cycles. This assay was used to quantitate CPT plasma concentrations in clinical samples to confirm clinical utility following NLG207 treatment in subjects with advanced prostate cancer.